Free Trial
NASDAQ:ATYR

aTyr Pharma Q3 2024 Earnings Report

aTyr Pharma logo
$0.84 0.00 (-0.08%)
Closing price 04:00 PM Eastern
Extended Trading
$0.84 0.00 (-0.26%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

aTyr Pharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.22
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

aTyr Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.13 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

aTyr Pharma Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

aTyr Pharma's Q1 2026 earnings is estimated for Wednesday, May 6, 2026, based on past reporting schedules

Earnings Documents

aTyr Pharma Earnings Headlines

aTyr Pharma (ATYR) to Release Quarterly Earnings on Wednesday
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.tc pixel
See More aTyr Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email.

About aTyr Pharma

aTyr Pharma (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling. Its lead program, ATYR1923, is being investigated for the treatment of pulmonary sarcoidosis, and additional pipeline candidates are advancing in preclinical and early clinical studies for oncology and neuromuscular disorders. aTyr’s platform allows for the rapid screening of protein interactions and the engineering of modulators with potential applications across multiple therapeutic areas.

Founded in 2005, aTyr Pharma completed its initial public offering in 2015 and has since entered into strategic collaborations to accelerate the development and potential commercialization of its product candidates. The company’s research and development activities span North America and Europe, and its leadership team brings together expertise in protein therapeutics, immunology, and clinical development. aTyr continues to leverage its platform to address unmet medical needs and to expand its pipeline through internal discovery and external partnerships.

View aTyr Pharma Profile